107 260

Cited 19 times in

The Efficacy of Hepatic Resection after Neoadjuvant Transarterial Chemoembolization (TACE) and Radiation Therapy in Hepatocellular Carcinoma Greater Than 5 cm in Size

Authors
 Sae Byeol Choi  ;  Kyung Sik Kim  ;  Young Nyun Park  ;  Jin Sub Choi  ;  Woo Jung Lee  ;  Jinsil Seong  ;  Kwang-Hyub Han  ;  Jong Tae Lee 
Citation
 JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.24(2) : 242-247, 2009 
Journal Title
 JOURNAL OF KOREAN MEDICAL SCIENCE 
ISSN
 1011-8934 
Issue Date
2009
MeSH
Adult ; Aged ; Antineoplastic Agents/therapeutic use ; Carcinoma, Hepatocellular/radiotherapy ; Carcinoma, Hepatocellular/surgery ; Carcinoma, Hepatocellular/therapy* ; Chemoembolization, Therapeutic* ; Combined Modality Therapy ; Doxorubicin/therapeutic use ; Female ; Humans ; Liver/surgery* ; Liver Neoplasms/radiotherapy ; Liver Neoplasms/surgery ; Liver Neoplasms/therapy* ; Male ; Middle Aged ; Neoplasm Staging ; Preoperative Care ; Prognosis ; Retrospective Studies ; Severity of Illness Index ; Survival Rate
Keywords
Carcinoma ; Hepatocellular ; Hepatic Resection ; Radiotherapy ; TACE
Abstract
In cases of large hepatocellular carcinoma (HCC), neoadjuvant treatment such as transarterial chemoembolization (TACE) and radiation therapy can be performed. The aim of this study was to evaluate the outcome of these treatments prior to hepatic resection. Between January 1994 and May 2007, 16 patients with HCC greater than 5 cm in size were treated with TACE and radiation therapy prior to hepatic resection. The clinicopathologic factors were reviewed retrospectively. Of the 16 patients, there were 14 men and two women, and the median age was 52.5 yr. TACE was performed three times in average, and the median radiation dosage was 45 Gy. The median diameter of tumor on specimen was 9.0 cm. The degree of tumor necrosis was more than 90% in 14 patients. The median survival time was 13.3 months. Five patients had survived more than 2 yr and there were two patients who had survived more than 5 yr. Although the prognosis of large HCC treated with neoadjuvant therapy is not satisfactory, some showed long-term survival loger than 5 yr. Further research will be required to examine the survival and disease control effect in a prospective randomized study
Files in This Item:
T200901279.pdf Download
DOI
10.3346/jkms.2009.24.2.242
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Kim, Kyung Sik(김경식) ORCID logo https://orcid.org/0000-0001-9498-284X
Park, Young Nyun(박영년) ORCID logo https://orcid.org/0000-0003-0357-7967
Seong, Jin Sil(성진실) ORCID logo https://orcid.org/0000-0003-1794-5951
Lee, Woo Jung(이우정) ORCID logo https://orcid.org/0000-0001-9273-261X
Lee, Jong Tae(이종태)
Choi, Sae Byeol(최새별)
Choi, Jin Sub(최진섭)
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/103866
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse